{
  "docId": "019de076-a4b3-719a-94d2-ca29be1b4679",
  "docSlug": "0f14c676100503df3bb87c658cc9d332",
  "documentTitle": "Fusion Pharmaceuticals | Investor Presentation Deck | 26 slides",
  "authorId": "fusion-pharmaceuticals",
  "authorName": "Fusion Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 26,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a 'before-after' logic to explain the transition from 177Lu to 225Ac.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de076-a4b3-719a-94d2-ca29be1b4679/22",
  "deckHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679",
  "deckJsonHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679.json",
  "deckAnchorHref": "/decks/019de076-a4b3-719a-94d2-ca29be1b4679#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "callout",
      "text": "Fusion acquired the small molecule 177Lu radiopharmaceutical, IPN-1087, from Ipsen",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd49cc29-6bdc-46b2-8dfd-c64ad26b8110",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.2,
        "x": 0.58,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Relative tumor volume (RTV) vs Days after treatment initiation",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9061ad2-b70b-4390-af28-6310abe80564",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.11,
        "y": 0.42
      },
      "kind": "image",
      "text": "Clinical imaging of CRC patient",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "853a814b-f8a9-46d2-94be-7eb5fc1b0bea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.02,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "Currently in Phase 1 dose escalation",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f6f6f78-022f-40eb-93cb-39d852b695d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 1,
        "x": 0,
        "y": 0.85
      },
      "kind": "title",
      "text": "FPI-2059 augments Fusion’s portfolio with a small molecule-based TAT in areas where there is high unmet medical need",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b854e5e-deba-4866-bcc1-ed89d87a7a94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "FPI-2059: A small molecule TAT targeting Neurotensin Receptor 1 (NTSR1)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dea120a-f6dc-41fb-9bd8-e64eb231e79a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "73edd2ab-985c-404a-99d6-69ba25b69305",
      "evidence": "The slide explicitly shows the transition from 177Lu to 225Ac with a directional arrow and performance comparison.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}